

**Amendments to the Claims**

Please cancel Claims 1-15, 18-51 and 53-74. Please amend Claims 16, 17 and 52. Please add new Claims 75-104. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

- 1-15. (Canceled)
16. (Currently amended) ~~The A method of claim 14 treating chronic lymphocytic leukemia in a subject, comprising the step of administering a cell that has been transfected with a nucleic acid comprising a nucleotide sequence encoding a,~~ wherein the isolated miR15 or miR16 gene product is administered by transfection of cells of to the subject.
17. (Currently amended) The method of claim Claim 16, wherein the cells are hematopoietic stem cells, cell is a chronic lymphocytic leukemia cells or prostate cancer cells cell.
- 18-51. (Canceled)
52. (Currently amended) ~~The A method of claim 50, wherein the isolated miR15 or miR16 gene product is administered by transfection of the miR15 or miR16 mediated cancer cells~~ treating a prostate cancer in a subject, comprising the step of administering a cell that has been transfected with a nucleic acid that comprises a nucleotide sequence encoding a miR15 gene product to the subject.
- 53-74. (Canceled)
75. (New) The method of Claim 16, wherein the cell is a hematopoietic stem cell.
76. (New) The method of Claim 16, wherein the nucleic acid is a component of a vector.

77. (New) The method of Claim 76, wherein the vector is selected from the group consisting of a recombinant plasmid vector and a recombinant viral vector.
78. (New) The method of Claim 76, wherein the vector includes a promoter selected from the group consisting of a U6 promoter, an H1 promoter, and a cytomegalovirus promoter.
79. (New) The method of Claim 77, wherein the recombinant viral vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, a retroviral vector, and a herpes viral vector.
80. (New) The method of Claim 79, wherein the retroviral vector is selected from the group consisting of a lentiviral vector, a Rhabdoviral vector, and a murine leukemia virus vector.
81. (New) The method of Claim 77, wherein the recombinant plasmid vector includes an expression vector.
82. (New) The method of Claim 16, wherein the nucleic acid is stably integrated into the genome of the cell.
83. (New) The method of Claim 16, wherein the cell is administered to the subject by parenteral administration.
84. (New) The method of Claim 83, wherein the parenteral administration is selected from the group consisting of an intravenous administration, an intraarterial administration, a peri-tissue injection, an intra-tissue injection, a subcutaneous injection, a subcutaneous infusion, and an inhalation.

85. (New) The method of Claim 83, wherein the parenteral administration comprises injection of the cell into a bone marrow of the subject.
86. (New) The method of Claim 16, wherein about  $10^5$  to about  $10^8$  cells per kilogram of body weight of the subject are administered.
87. (New) The method of Claim 16, wherein the cell is a cell that has been isolated from the subject.
88. (New) The method of Claim 87, wherein the cell that has been isolated from the subject is cultured prior to transfection with the nucleic acid.
89. (New) The method of Claim 52, wherein administration of the cell inhibits proliferation of a prostate cancer cell in the subject.
90. (New) The method of Claim 52, wherein administration of the cell inhibits proliferation of a cell in a metastatic tumor of prostate origin in the subject.
91. (New) The method of Claim 52, wherein the nucleic acid is a component of a vector.
92. (New) The method of Claim 91, wherein the vector is selected from the group consisting of a recombinant plasmid vector and a recombinant viral vector.
93. (New) The method of Claim 91, wherein the vector includes a promoter selected from the group consisting of a U6 promoter, an H1 promoter, and a cytomegalovirus promoter.
94. (New) The method of Claim 92, wherein the recombinant viral vector is selected from the group consisting of an adenoviral vector, an adeno-associated viral vector, a retroviral vector, and a herpes viral vector.

95. (New) The method of Claim 94, wherein the retroviral vector is selected from the group consisting of a lentiviral vector, a Rhabdoviral vector, and a murine leukemia virus vector.
96. (New) The method of Claim 92, wherein the recombinant plasmid vector includes an expression vector.
97. (New) The method of Claim 52, wherein the nucleic acid is stably integrated into the genome of the cell.
98. (New) The method of Claim 52, wherein the cell is administered to the subject by parenteral administration.
99. (New) The method of Claim 98, wherein the parenteral administration is selected from the group consisting of an intravenous administration, an intraarterial administration, a peri-tissue injection, an intra-tissue injection, a subcutaneous injection, a subcutaneous infusion, and an inhalation.
100. (New) The method of Claim 98, wherein the parenteral administration comprises injection of the cell into a tumor.
101. (New) The method of Claim 100, wherein the tumor is selected from the group consisting of a prostate tumor and a metastatic tumor of prostate origin.
102. (New) The method of Claim 52, wherein about  $10^5$  to about  $10^8$  cells per kilogram of body weight of the subject are administered.
103. (New) The method of Claim 52, wherein the cell is a cell that has been isolated from the subject.

104. (New) The method of Claim 103, wherein the cell that has been isolated from the subject is cultured prior to transfection with the nucleic acid.